Immune reconstitution and cidofovir administration rescue human adenovirus hepatitis after allogeneic hematopoietic cell transplantation.
Takahiro TomodaAkira NishimuraTakahiro KamiyaKumi InoueHarutaka KatanoShun IidaAkihiro HoshinoTakeshi IsodaKohsuke ImaiMichiko KajiwaraMasatoshi TakagiHirokazu KaneganeNozomu HanaokaTomohiro MorioPublished in: Transplant immunology (2024)
Human adenovirus infection (HAdV) may be fatal in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Cidofovir is effective in only a part of the post-HCT HAdV infection. Therefore, posttransplant immune reconstitution is important for HAdV clearance. We describe the detailed immune reconstitution and response of adenovirus-specific T cells in a patient with inborn errors of immunity who had disseminated HAdV infection with hepatitis post-HCT and was treated with cidofovir. Though the patient received cidofovir for only 19 days starting from Day 72 after HCT because of renal dysfunction, we observed T-cell reconstitution, a decrease in HAdV copy number, and amelioration of the symptoms of HAdV infection after Day 90. We initially observed expanded NK and CD8 + CD45RO + memory subsets and later gradual increase of naïve T cells eveloped after cessation of cidofovir treatment. An increase in adenovirus-specific IFN-γ secretion from 2 to 4 months after HCT was confirmed by ELISpot assay. The progression of immune reconstitution and cidofovir treatment are considered to have contributed to survival in this patient. Optimization of transplantation methods, prompt appropriate antiviral medication, and virus-specific T-cell therapy would be necessary as the better strategy for systemic HAdV infection.
Keyphrases
- cell therapy
- copy number
- patients undergoing
- stem cell transplantation
- bone marrow
- healthcare
- gene therapy
- dna methylation
- immune response
- mesenchymal stem cells
- emergency department
- physical activity
- pluripotent stem cells
- cell proliferation
- low dose
- induced pluripotent stem cells
- peripheral blood
- working memory
- replacement therapy
- hematopoietic stem cell